A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, T R J, Colston, K W, Lofts, F J, Cunningham, D, Anthoney, D A, Gogas, H, de Bono, J S, Hamberg, K J, Skov, T, Mansi, J L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375305/
https://www.ncbi.nlm.nih.gov/pubmed/11875725
http://dx.doi.org/10.1038/sj.bjc.6600162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375305/
https://www.ncbi.nlm.nih.gov/pubmed/11875725
http://dx.doi.org/10.1038/sj.bjc.6600162

Ejemplares similares